Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Pfizer (Rights to Novel LAMA Respiratory Compound)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Right to develop a generic drug. The asset comprises of exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. The development of the compounds will generate combination therapies and that these products will utilize the multi-dose dry powder inhaler technology.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • New York, NY
  • United States

Pfizer (Rights to Novel LAMA Respiratory Compound) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Pfizer (Rights to Novel LAMA Respiratory Compound)‘s full profile, request access.

Request full access to PitchBook

Pfizer (Rights to Novel LAMA Respiratory Compound) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Pfizer (Rights to Novel LAMA Respiratory Compound)‘s full profile, request access.

Request full access to PitchBook